Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma
Background: Stage IV melanoma has a poor prognosis with a median survival of 3-11 months from diagnosis of distant metastases. Response rates in first-line regimens range around 15-20%. Non-responders have a median survival around 6 months. Currently, no second-line treatment in advanced melanoma ha...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
December 08, 2004
|
| In: |
Onkologie
Year: 2004, Jahrgang: 27, Heft: 6, Pages: 540-544 |
| ISSN: | 1423-0240 |
| DOI: | 10.1159/000081335 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000081335 Verlag, lizenzpflichtig, Volltext: https://www.karger.com/Article/FullText/81335 
|
| Verfasserangaben: | W. Fink, C. Zimpfer-Rechner, A. Thoelke, R. Figl, M. Kaatz, S. Ugurel, D. Schadendorf |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1742643833 | ||
| 003 | DE-627 | ||
| 005 | 20220819052312.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201211s2004 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000081335 |2 doi | |
| 035 | |a (DE-627)1742643833 | ||
| 035 | |a (DE-599)KXP1742643833 | ||
| 035 | |a (OCoLC)1341383600 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Fink, Wolfram |d 1973- |e VerfasserIn |0 (DE-588)123096685 |0 (DE-627)706159268 |0 (DE-576)293553777 |4 aut | |
| 245 | 1 | 0 | |a Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma |c W. Fink, C. Zimpfer-Rechner, A. Thoelke, R. Figl, M. Kaatz, S. Ugurel, D. Schadendorf |
| 246 | 3 | 0 | |a two |
| 264 | 1 | |c December 08, 2004 | |
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 11.12.2020 | ||
| 520 | |a Background: Stage IV melanoma has a poor prognosis with a median survival of 3-11 months from diagnosis of distant metastases. Response rates in first-line regimens range around 15-20%. Non-responders have a median survival around 6 months. Currently, no second-line treatment in advanced melanoma has been established. Patients and Methods: In a clinical phase II study we evaluated the efficacy of liposomal doxorubicin (Caelyx?) in 30 patients (17 m, 13 f) with progressing metastatic melanoma who had failed a previous chemotherapy. Liposomal doxorubicin was given in an outpatient setting at a dose of 50 mg/m2 i.v. on d1, d22, d43 and d64, subsequently at 40 mg/m2 at d85 before first staging and in 4-week intervals thereafter. Treatment was very well tolerated with 100 cycles given in total. Response rate, survival time, time-to-progression and toxicity were assessed. Results: Erythrodysesthesia was the most severe toxicity in 6% at CTC grade 3. Liposomal doxorubicin was of limited clinical efficacy with 21 patients progressing within the first 12 weeks. However, 7 patients were treated 3-9 months and were stable for >90 days, achieving 5 SD, 1 PR and 1 CR. Median survival after initiation of second-line treatment was 214 days (95% CI: 151-304 days) with 7 patients surviving >300 and 5 patients >400 days. Conclusions: Liposomal doxorubin as monotherapy is well tolerated but of limited clinical efficacy. Whether the survival benefit of a significant proportion of patients (20%) holds true in larger cohorts and whether the efficacy of liposomal doxorubicin can be improved by combinations without compromising the low toxicity profile needs further studies. | ||
| 700 | 1 | |a Figl, Adina |d 1975- |e VerfasserIn |0 (DE-588)1146398816 |0 (DE-627)1005834245 |0 (DE-576)186024819 |4 aut | |
| 700 | 1 | |a Figl, Robert |d 1967- |e VerfasserIn |0 (DE-588)129776971 |0 (DE-627)47950475X |0 (DE-576)297830368 |4 aut | |
| 700 | 1 | |a Ugurel, Selma |d 1971- |e VerfasserIn |0 (DE-588)122030923 |0 (DE-627)081693532 |0 (DE-576)293057567 |4 aut | |
| 700 | 1 | |a Schadendorf, Dirk |d 1960- |e VerfasserIn |0 (DE-588)11142576X |0 (DE-627)499566076 |0 (DE-576)289702275 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Onkologie |d Basel : Karger, 1978 |g 27(2004), 6, Seite 540-544 |h Online-Ressource |w (DE-627)300595417 |w (DE-600)1483097-8 |w (DE-576)105282863 |x 1423-0240 |7 nnas |a Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma |
| 773 | 1 | 8 | |g volume:27 |g year:2004 |g number:6 |g pages:540-544 |g extent:5 |a Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma |
| 856 | 4 | 0 | |u https://doi.org/10.1159/000081335 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.karger.com/Article/FullText/81335 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20201211 | ||
| 993 | |a Article | ||
| 994 | |a 2004 | ||
| 998 | |g 11142576X |a Schadendorf, Dirk |m 11142576X:Schadendorf, Dirk |d 50000 |e 50000PS11142576X |k 0/50000/ |p 7 |y j | ||
| 998 | |g 122030923 |a Ugurel, Selma |m 122030923:Ugurel, Selma |p 6 | ||
| 998 | |g 129776971 |a Figl, Robert |m 129776971:Figl, Robert |d 50000 |e 50000PF129776971 |k 0/50000/ |p 4 | ||
| 998 | |g 1146398816 |a Figl, Adina |m 1146398816:Figl, Adina |d 140000 |e 140000PF1146398816 |k 0/140000/ |p 3 | ||
| 999 | |a KXP-PPN1742643833 |e 382349385X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"5 S."}],"person":[{"display":"Fink, Wolfram","role":"aut","given":"Wolfram","family":"Fink","roleDisplay":"VerfasserIn"},{"role":"aut","display":"Figl, Adina","given":"Adina","family":"Figl","roleDisplay":"VerfasserIn"},{"display":"Figl, Robert","role":"aut","given":"Robert","family":"Figl","roleDisplay":"VerfasserIn"},{"family":"Ugurel","roleDisplay":"VerfasserIn","given":"Selma","display":"Ugurel, Selma","role":"aut"},{"role":"aut","display":"Schadendorf, Dirk","given":"Dirk","family":"Schadendorf","roleDisplay":"VerfasserIn"}],"name":{"displayForm":["W. Fink, C. Zimpfer-Rechner, A. Thoelke, R. Figl, M. Kaatz, S. Ugurel, D. Schadendorf"]},"relHost":[{"recId":"300595417","pubHistory":["1.1978 - 36.2013"],"disp":"Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanomaOnkologie","note":["Gesehen am 15.12.2023"],"title":[{"subtitle":"international journal for cancer research and treatment","title_sort":"Onkologie","title":"Onkologie"}],"id":{"issn":["1423-0240"],"zdb":["1483097-8"],"eki":["300595417"]},"language":["ger"],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"publisher":"Karger","dateIssuedDisp":"1978-2013","publisherPlace":"Basel","dateIssuedKey":"1978"}],"part":{"year":"2004","extent":"5","pages":"540-544","text":"27(2004), 6, Seite 540-544","volume":"27","issue":"6"},"physDesc":[{"extent":"Online-Ressource"}]}],"origin":[{"dateIssuedKey":"2004","dateIssuedDisp":"December 08, 2004"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"recId":"1742643833","title":[{"title":"Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma","title_sort":"Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma"}],"id":{"doi":["10.1159/000081335"],"eki":["1742643833"]},"note":["Gesehen am 11.12.2020"]} | ||
| SRT | |a FINKWOLFRACLINICALPH0820 | ||